BD Acquires MedKeeper to Offer Cloud-Based Connected Pharmacy Software

ByLance T. Lee

Jul 28, 2022

MedKeeper’s platform will be part of the company’s existing portfolio of connected medication management capabilities. By combining MedKeeper’s platform with BD’s extensive technology expertise, companies will strive to optimize compound drug preparation, a critical need in today’s pharmacy.

“Preparing the right dose for patients requires a combination of factors including personnel, training and compliance. Pharmacy managers need IV workflow management technology that is customized to their needs and that works in their environment,” said Mike Garrison, Global President of Medication Management Solutions at BD. “Adding MedKeeper to our portfolio will allow us to offer our customers easy-to-use, customizable solutions that make significant and incremental advancements in IV workflow management.”

Many pharmacies today use a combination of manual and technical tools for their IV workflow management system. The addition of MedKeeper to BD’s portfolio of medication management solutions will further strengthen the company’s ability to provide solutions that best meet customer needs today and in the future.

“Demands in today’s pharmaceutical environment, such as COVID-related labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible and directed workflow, inventory tracking and reporting needs across sterile and non-sterile preparations,” says Garrison. “Manual, time-consuming procedures that may have been ‘good enough’ in the past can now be replaced and complemented by software that empowers pharmacists to deliver superior care.”

BD and MedKeeper will work to provide customers with the flexibility and capabilities to meet industry standards for compound drug preparation, incorporating the latest regulatory guidelines. Together, the companies are committed to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiencies to their frontline clinicians.

The transaction is not expected to be material to BD’s fiscal 2022 financial results.

About comics
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and care delivery. The company supports heroes on the frontlines of healthcare by developing innovative technologies, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 70,000 employees have a passion and commitment to help improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease, and advance capabilities of researchers to develop the next generation of diagnostics and therapies. BD is present in virtually every country and partners with organizations around the world to solve some of the world’s toughest health issues. By working closely with its customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.

This press release contains certain estimates and other forward-looking statements (as defined by federal securities laws) regarding the expected benefits of the acquisition of MedKeeper. Forward-looking statements are generally accompanied by words such as “will”, “expect”, or similar words, phrases or expressions. These statements are based on the current expectations of BD management and are subject to a number of risks and uncertainties regarding MedKeeper’s business and the acquisition, and actual results may differ materially from the anticipated results described, implied or projected in any forward-looking statement. These risks and uncertainties include, but are not limited to, the risks of integrating MedKeeper technology, software and people into BD, and the time and resources required to do so and the possibility that anticipated benefits of the acquisition are not realized or will not be realized in the time anticipated; competitive factors, including the development of new technologies by other companies and price and market share pressures; changes in healthcare or other government regulations; risks relating to the ability to maintain favorable agreements and relationships with suppliers; changes in regional, domestic or foreign economic conditions; and other factors discussed in BD’s filings with the Securities Exchange Commission. BD does not intend to update forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.




Trey Hollern

Francesca DeMartino

Director, Public Relations

SVP, Head of Investor Relations



[email protected]

[email protected]

COMIC SOURCE (Becton, Dickinson and Company)

Source link